JNJ to Acquire Firefly Bio to Expand KRAS-Targeted Degrader Antibody Platform
Johnson & Johnson will acquire Firefly Bio for $1 billion in cash to bolster its oncology pipeline with Firefly's Firelink degrader antibody conjugate (DAC) platform, designed to target KRAS-driven solid tumors by delivering selective protein degraders to cancer cells while sparing healthy tissue, with closing expected later this year pending regulatory approvals.